TriGemX Bio Appoints Doug Pagán to its Board of Directors

Doug Pagán brings more than 20 years of experience in business growth, operations and value creation. He currently serves as Chief Financial Officer at Kailera Therapeutics and previously held CFO and COO roles at Atalanta Therapeutics, where he remains on the Board of Directors.

Earlier, Pagán was CFO and COO of Jnana Therapeutics until its acquisition by Otsuka Pharmaceutical. He also served as CFO at Dicerna Pharmaceuticals, KSQ Therapeutics and Paratek Pharmaceuticals, along with leadership roles at Acceleron and Biogen.

Read More:SignSplit Secures $400 Million in Strategic Seed Funding

Pagán has also served on the boards of Ziopharm Oncology and Timberlyne Therapeutics. He holds an MBA in Finance and Accounting from Columbia Business School and a BSE in Chemical Engineering from Princeton University.

"I'm honored to join the TriGemX Bio Board of Directors at this critical time of acceleration," said Doug Pagán, CFO of Kailera. "I look forward to partnering with Jeff, my fellow directors, and the management team as they work to bring elismetrep to patients suffering from migraine."

"We are thrilled to welcome Doug to our Board of Directors at this pivotal moment," said Jeff Goater, CEO of TriGemX Bio. "As we advance Phase 3 development of elismetrep and prepare for our next stage of growth, Doug's financial expertise and deep industry experience helping biotechnology companies scale, create value, and navigate key inflection points will be an important asset.

About TriGemX Bio

TriGemX Bio is a biotechnology company developing elismetrep, a potential first-in-class TRPM8 channel blocker for migraine treatment. The companys approach is based on its research into neural signaling pathways and the role of TRPM8 in migraine.

Read More:Supabase Raises $150M in Funding Led by GIC